Supplements
curcumin decreases inflammatory biomarkers
In plain terms: Does turmeric/curcumin meaningfully lower inflammation in people?
Strong support Supplements 🔬 Includes disconfirming
Part of: 🧪 turmeric & curcumin
RefutedContestedStrong support
consensus score 0.62
Partly — pooled trials show curcumin lowers CRP/IL-6, but the evidence is low-certainty, heterogeneous, publication-biased, and null in the most rigorous analyses.
📅 Last reviewed: 2026-07-14 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
MechanismIn-vitroAnimalObservationalRCTMeta-analysis
How the studies fall
9 support 0 contradict 3 tested null 3 mixed · 15 sources, 9 independent groups
What the evidence shows
Pooled trials show curcumin lowering C-reactive protein and interleukin-6, but the evidence is weakest where it should be strongest: the meta-analyses are heterogeneous, formulation-dependent and publication-biased, and the more rigorous syntheses are null, including seven trials in rheumatoid arthritis and lupus and a 19-trial review in chronic inflammatory disease.
The evidence (16)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Gorabi AM, Abbasifard M, Imani D, Aslani S, Razi B, Alizadeh S, Bagheri-Hosseinabadi Z, Sathyapalan T, Sahebkar A 2022 · Phytother Res | meta-analysis | supports | moderate | Updated meta-analysis showed curcumin significantly lowered CRP and hs-CRP, with stronger effects at longer durations. |
| Qiu L, Gao C, Wang H, Ren Y, Li J, Li M, Du X, Li W, Zhang J 2023 · Frontiers in Endocrinology | meta-analysis | mixed | low | In metabolic syndrome patients, curcumin improved inflammatory and oxidative stress indices, but the evidence base was small and low-certainty. |
| Sahebkar A 2014 · Phytotherapy Research | meta-analysis | mixed | moderate | Curcuminoids lowered circulating CRP overall but findings across clinical trials were inconsistent, dependent on formulation and bioavailability. |
| Liu AJ, Wu PC, Chen YP, Chu HT, Chang HH 2025 · Inflammation Research | meta-analysis | tested-null | moderate | Meta-analysis of 7 RCTs (314 patients; 6 RA, 1 SLE), curcumin or Curcuma longa extract vs placebo or standard therapy for 8-12 weeks. Underpowered trend toward the claim, not significant: CRP pooled SMD -1.65 (95% CI -3.88 to 0.58; 4 studies, I2 91.6%); ESR SMD -1.49 (-3.71 to 0.72; 6 studies, I2 91.7%). Without the outlying Amalraj trial, CRP SMD -0.34 (-0.675 to 0.004), I2 0%. DAS-28 (disease activity, not a biomarker) SMD -2.34 (-5.13 to 0.44). The authors report 'no significant effect'. |
| White CM, Pasupuleti V, Roman YM, Li Y, Hernandez AV 2019 · Pharmacological Research | meta-analysis | tested-null | moderate | White 2019 SR/MA, 19 RCTs (turmeric 5, n=356; curcumin 14, n=988), chronic inflammatory disease, 4-16 wk: 'turmeric or curcumin did not significantly decrease levels of CRP (MD -2.71 mg/L, 95%CI -5.73 to 0.31, p = 0.08, 5 studies), hsCRP (MD -1.44 mg/L, 95%CI -2.94 to 0.06, p = 0.06, 6 studies)', IL-1b, IL-6 (-0.71, -1.68 to 0.25) or TNF-a (-1.23, -3.01 to 0.55, 7 studies). Null on a directional claim = contradicts; all estimates lean toward reduction (underpowered, 2-7 studies per marker). 'High heterogeneity of effects was observed for all markers across studies, except hsCRP' -> quality moderate. Underpowered trend toward the claim (point estimate favours it, interval includes no effect): graded tested-null per CONVENTIONS §5 second clarification 2026-09-26. |
| Kavyani Z, Najafi K, Naghsh N, Karvane HB, Musazadeh V 2024 · Prostaglandins Other Lipid Mediat | meta-analysis | supports | moderate | Meta-analysis of meta-analyses: 'Pooled estimates of 21 meta-analyses revealed that curcumin significantly reduced CRP (weighted mean difference (WMD) = -0.87; 95 % CI: - 1.14, - 0.59, P< 0.001)'. Units are syntheses, so it re-pools RCTs the vault counts via those MAs. Review — zero weight. |
| Yaikwawong M, Kamdee K, Chuengsamarn S 2026 · Int J Mol Sci | RCT | supports | moderate | In obese type 2 diabetes patients curcumin reduced inflammation and neutrophil-to-lymphocyte ratio versus placebo. |
| Dehzad MJ, Ghalandari H, Nouri M, Askarpour M 2023 · Cytokine | meta-analysis | supports | moderate | Across 66 RCTs, turmeric/curcumin significantly reduced CRP (-0.58 mg/L), TNF-alpha, and IL-6, though with high between-study heterogeneity. |
| Hsueh HC, Ho GR, Tzeng SI, Liang KH, Horng YS 2025 · BMC Complement Med Ther | meta-analysis | mixed | low | In knee osteoarthritis RCTs curcumin lowered some serum inflammatory markers but effects were inconsistent across biomarkers. |
| Ghoflchi S, Jalili-Nik M, Hashemy SI, Karav S, Hosseini H, Sahebkar A 2026 · Endocrinol Diabetes Metab | meta-analysis | tested-null | low | SR/MA of 7 RCTs of nanocurcumin in T2DM; CRP pool 5 trials, 303 participants: SMD -0.78 (95% CI -1.58 to 0.05, p=0.052). Underpowered trend toward lower CRP; significant only after excluding Mansour et al. in leave-one-out. CRP was the only inflammatory marker pooled; TAC/MDA gains are oxidative-stress markers. Publication bias cannot be excluded (authors). |
| Bahari H, Omidian K, Asadi Z, Golafrouz H, Rafiei H 2025 · Inflammopharmacology | meta-analysis | supports | low | In prediabetes/diabetes, curcumin significantly reduced CRP, TNF-alpha, and IL-6, but overall certainty was rated low with detected publication bias for CRP. |
| Askari MA, Golpour-Hamedani S, Khorvash F, Yegdaneh A, Vajdi M 2026 · Nutrition journal | RCT | supports | moderate | RCT (n=60 migraine patients): 8 weeks of Mixodin (300mg curcumin + gingerol + piperine) significantly reduced serum hs-CRP vs placebo (P=0.001). Confounded by co-administered gingerol/piperine, so effect cannot be attributed to curcumin alo |
| Tabrizi R, Vakili S, Akbari M, Mirhosseini N, Lankarani KB, Rahimi M, Mobini M, Jafarnejad S, Vahedpoor Z, Asemi Z 2019 · Phytother Res | meta-analysis | supports | moderate | Curcumin supplementation significantly decreased IL-6, hs-CRP and MDA across 15 RCTs though TNF-alpha was unchanged. |
| Pan C, Wang S, Yang Y, Hu J, Pan Y 2026 · Frontiers in nutrition | meta-analysis | supports | moderate | Systematic review of 20 RCTs (curcumin 500-1500mg/day + piperine): 15/20 trials showed significant decreases in CRP, hs-CRP, and IL-6. Bioavailability was piperine-enhanced (not curcumin alone), and formulations/doses varied widely across s |
| Bourbour F, Mahdavi B, Naghshi N, Yari Z, Hosseini SM, Kalbasi S, Sohrab G 2026 · Food science & nutrition | RCT | supports | moderate | Double-blind RCT (n=57, Hashimoto's thyroiditis): 1500mg/day curcumin added to an anti-inflammatory diet significantly reduced IL-6 (p=0.009) and NF-κB (p=0.019) vs placebo; hs-CRP fell numerically but was not statistically significant (p=0 |
| Lee YM, Kim Y 2024 · Nutrients | meta-analysis | supports | moderate | Review of meta-analyses of RCTs found curcumin's anti-inflammatory effects on chronic metabolic disease real but heterogeneous and formulation-dependent. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.